Citations

Clear

139 citation(s) found for "Anderson, Kenneth C".

PB2137 SUBGROUP ANALYSIS OF PATIENTS FROM CANADA AND THE UNITED STATES IN THE PHASE 3 FIRST TRIAL IN TRANSPLANT‐INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA
Belch, Andrew R. , White, Darrell , Cheung, M., Chen, C., Shustik, Chaim, Song, Kevin , Tosikyan, Axel, Kotey, Stanley, Brown, Diane , Srinivasan, S. , Bahlis, Nizar Jacques , Cheung, M., Dispenzieri, Angela , Anderson, Kenneth C. , Brown, D., Robinson, S., Facon, Thierry T.F.

Mayo Clinic

HemaSphere | June 17, 2019 | Volume: 3 | Issue: S1 | Pages: 962

10.1097/01.hs9.0000567032.31064.27 Get It

Background:The pivotal FIRST trial, the largest study conducted in transplant‐ineligible (TNE) patients (pts) with newly diagnosed multiple myeloma (NDMM), examined lenalidomide plus low‐dose dexamethasone until disease progression (Rd continuous), Rd for 18 cycles (Rd18), and melphalan, prednisone, and thalidomide (MPT). The study, conducted in 18 countries in Europe, North America, and Asia Pacific, demonstrated that Rd continuous significantly improved progression‐free survival (PFS) vs MPT (median 26.0 vs 21.9 mos; HR, 0.69; 95% CI, 0.59‐0.79; P < .00001). PFS was similarly extended for Rd continuous vs Rd18 (median 21.0 mos; HR, 0.70; 95% CI, 0.60‐0.81). Furthermore, median overall survival (OS) was significantly longer with Rd continuous vs MPT (median 59.1 vs 49.1 mos; HR, 0.78; 95% CI, 0.67‐0.92; P = .0023). These results support the use of frontline oral, alkylator‐free continuous therapy for TNE NDMM pts and established Rd continuous as a standard of care as reflected by clinical guidelines in Canada, the US, and Europe.Aims:To report outcomes in the subset of patients from Canada and the US.MethodsPts with TNE NDMM were randomized 1:1:1 to Rd continuous (with lenalidomide given on days 1‐21 of 28‐day cycles until disease progression), Rd18 (with lenalidomide given on days 1‐21 of eighteen 28‐day cycles), or MPT (twelve 42‐day cycles). Rd18 and MPT were both 72 weeks in duration. Stratification factors included country and Rd continuous vs MPT was the primary comparison. The primary endpoint was PFS and secondary endpoints included OS, time to next therapy (TTNT) and safety. Time from randomization to second progression or death (PFS2) was an exploratory analysis. Response assessment used for PFS and PFS2 analysis was determined by investigators based on International Myeloma Working Group criteria. Data is presented as of the January 21, 2016 cutoff used for the final OS analysis.Results:A total of 312 pts from Canada (n = 252) and the US (n = 60) were enrolled (104 in each arm). Consistent with results from the intent‐to‐treat (ITT) analysis, the Canada/US subgroup also demonstrated a significant improvement in PFS with Rd continuous vs MPT (median 29.3 vs 20.2 mos; HR, 0.69; 95% CI, 0.49‐0.97; P = .03326) and an improvement vs Rd18 (median 21.9 mos; HR, 0.72; 95% CI, 0.51‐1.02; Table). Median OS was 56.9 vs 46.8 mos for Rd continuous vs MPT (HR, 0.77; 95% CI, 0.53‐1.11; P = .15346). Median PFS2 was longer for Rd continuous vs MPT (median 39.3 vs 35.1 mos; HR, 0.69; 95% CI 0.50‐0.95) as was TTNT (median 39.1 vs 24.6 mos; HR, 0.54; 95% CI, 0.37‐0.78). Additional details, including safety data, will be presented at the meeting.Summary/Conclusion:In the Canada/US subpopulation of pts from FIRST, Rd continuous extended median PFS by 9 mos vs MPT and > 7 mos vs Rd18. Rd continuous also delayed median TTNT > 14 mos and resulted in a longer PFS2 vs MPT, suggesting that the benefit from frontline Rd continuous is maintained at relapse. These results are consistent with that from the ITT population confirming the advantage of Rd continuous vs MPT in the Canada/US subgroup and supporting the role of Rd continuous as a standard of care for TNE pts with NDMM. The efficacy observed with Rd continuous raises the question on the role of immunostimulatory effects by the immunomodulatory agents in NDMM.image
Precision medicine in multiple myeloma: are we there yet?
Auclair, Daniel , Kumar, Shaji , Lonial, Sagar , Anderson, Kenneth C.

Mayo Clinic

Expert Review of Precision Medicine and Drug Development | February 7, 2019 | Volume: 4 | Issue: 2 | Pages: 51-53

10.1080/23808993.2019.1578172 Get It

Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).
Richardson, Paul G. , Usmani, Saad Zafar, Bensinger, William, Dubin, Franck , Liu, Qianying , Vitse, Olivier , Mıkhael, Joseph , Richardson, Paul Gerard Guy , Usmani, Saad Zafar, Raje, Noopur , Anderson, Kenneth C.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8038-8038

10.1200/jco.2018.36.15_suppl.8038 Get It

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
Walker, Brian A. , Mavrommatis, Konstantinos , Wardell, Christopher P. , Ashby, Cody , Bauer, Michael , Davies, Faith E. , Hoering, Antje , Samur, Mehmet , Towfic, Fadi , Flynt, Erin , Yu, Zhinuan, Yang, Zhihong, Rozelle, Dan , Obenauer, John C. , Trotter, Matthew , Auclair, Daniel , Keats, Jonathan J. , Bolli, Niccolò , Fulciniti, Mariateresa , Szalat, Raphaël , Moreau, Philippe , Durie, Brian G.M. , Stewart, A. Keith, Goldschmidt, Hartmut , Sonneveld, Pieter , Miguel, Jesús F. San , Jackson, Graham , Avet‐Loiseau, Hervé , Munshi, Nikhil , Thakurta, Anjan , Morgan, Gareth J. , Moreau, Philippe , Bolli, Niccolo' , San-Miguel, Jesus , Davies, Faith E , Keats, Jonathan J , Walker, Brian A , Morgan, Gareth J , Rosenthal, Adam , Wang, Hongwei , Qu, Pingping , Ortiz, María , Raab, Marc S. , Einsele, Hermann , Lonial, Sagar , Anderson, Kenneth C. , Flynt, Erin , Samur, Mehmet K , Szalat, Raphael

Mayo Clinic

Blood | June 8, 2018 | Volume: 132 | Issue: 6 | Pages: 587-597

10.1182/blood-2018-03-840132 | PMID 29884741 Get It

Key Points Using the largest set of patients with newly diagnosed myeloma, we identified 63 mutated driver genes. We identified oncogenic dependencies, particularly relating to primary translocations, indicating a nonrandom accumulation of genetic hits.
Germline Lysine-Specific Demethylase 1 ( LSD1/KDM1A ) Mutations Confer Susceptibility to Multiple Myeloma
Wei, Xiaomu , Calvo-Vidal, M. Nieves, Chen, Siwei , Wu, Gang , Revuelta, María V. , Zhang, Jinghui , Walsh, Michael F. , Nichols, Kim E. , Vijai, Joseph , Snyder, Carrie, Vachon, Celine M. , McKay, James , Wang, Shuping , Jayabalan, David , Jacobs, Lauren , Becirovic, Dina, Waller, Rosalie G., Artomov, Mykyta , Viale, Agnès , Patel, Jayeshkumar , Curtin, Karen , Salama, Mohamed E. , Atanackovic, Djordje , Niesvizky, Rubén, Godley, Lucy A. , Churpek, Jane E. , Dumontet, Charles , Lynch, Henry T., Camp, Nicola J. , Offit, Kenneth , Klein, Robert J. , Lipkin, Steven M. , Waller, Rosalie G. , Griffin, R. L. , Joseph, Vijai , Revuelta, Maria , Waller, Rosalie G , Godley, Lucy A , Sun, Jian Hua , Vachon, Celine M. , Waller, Rosalie G., Phillip, Jude M. , Chen‐Kiang, Selina , Landgren, Ola , Slager, Susan L. , Garber, Judy E. , Anderson, Kenneth C. , Daly, Mark J. , Roeder, Robert G. , Mullighan, Charles G. , Yu, Haiyuan , Cerchietti, Leandro C. A. , Wu, Gang , Nichols, Kim E , Griffin, Rosalie , Klein, Robert , Churpek, Jane E , Churpek, Jane

Mayo Clinic

Cancer Research | March 20, 2018 | Volume: 78 | Issue: 10 | Pages: 2747-2759

10.1158/0008-5472.can-17-1900 | PMID 29559475 Get It

Abstract Given the frequent and largely incurable occurrence of multiple myeloma, identification of germline genetic mutations that predispose cells to multiple myeloma may provide insight into disease etiology and the developmental mechanisms of its cell of origin, the plasma cell (PC). Here, we identified familial and early-onset multiple myeloma kindreds with truncating mutations in lysine-specific demethylase 1 (LSD1/KDM1A), an epigenetic transcriptional repressor that primarily demethylates histone H3 on lysine 4 and regulates hematopoietic stem cell self-renewal. In addition, we found higher rates of germline truncating and predicted deleterious missense KDM1A mutations in patients with multiple myeloma unselected for family history compared with controls. Both monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma cells have significantly lower KDM1A transcript levels compared with normal PCs. Transcriptome analysis of multiple myeloma cells from KDM1A mutation carriers shows enrichment of pathways and MYC target genes previously associated with myeloma pathogenesis. In mice, antigen challenge followed by pharmacologic inhibition of KDM1A promoted PC expansion, enhanced secondary immune response, elicited appearance of serum paraprotein, and mediated upregulation of MYC transcriptional targets. These changes are consistent with the development of MGUS. Collectively, our findings show that KDM1A is the first autosomal-dominant multiple myeloma germline predisposition gene providing new insights into its mechanistic roles as a tumor suppressor during post-germinal center B-cell differentiation. Significance: KDM1A is the first germline autosomal dominant predisposition gene identified in multiple myeloma and provides new insights into multiple myeloma etiology and the mechanistic role of KDM1A as a tumor suppressor during post-germinal center B-cell differentiation. Cancer Res; 78(10); 2747–59. ©2018 AACR.
Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update Summary
Ismaila, Nofisat , Kyle, Robert A. , Anderson, Kenneth C.

Mayo Clinic

Journal of Oncology Practice | March 8, 2018 | Volume: 14 | Issue: 4 | Pages: 266-269

10.1200/jop.17.00013 | PMID 29517956 Get It

Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update
Ismaila, Nofisat , Flynn, Patrick J. , Halabi, Susan , Ogaily, Mohammed S., Omel, Jim, Roodman, G. David, Yee, Gary C., Kyle, Robert A. , Halabi, Susan , Anderson, Kenneth C. , Jagannath, Sundar , Raje, Noopur

Mayo Clinic

Journal of Clinical Oncology | January 17, 2018 | Volume: 36 | Issue: 8 | Pages: 812-818

10.1200/jco.2017.76.6402 | PMID 29341831 Get It

Purpose To update guideline recommendations on the role of bone-modifying agents in multiple myeloma. Methods An update panel conducted a targeted systematic literature review by searching PubMed and the Cochrane Library for randomized controlled trials, systematic reviews, meta-analyses, clinical practice guidelines, and observational studies. Results Thirty-five relevant studies were identified, and updated evidence supports the current recommendations. Recommendations For patients with active symptomatic multiple myeloma that requires systemic therapy with or without evidence of lytic destruction of bone or compression fracture of the spine from osteopenia on plain radiograph(s) or other imaging studies, intravenous administration of pamidronate 90 mg over at least 2 hours or zoledronic acid 4 mg over at least 15 minutes every 3 to 4 weeks is recommended. Denosumab has shown to be noninferior to zoledronic acid for the prevention of skeletal-related events and provides an alternative. Fewer adverse events related to renal toxicity have been noted with denosumab compared with zoledronic acid and may be preferred in this setting. The update panel recommends that clinicians consider reducing the initial pamidronate dose in patients with preexisting renal impairment. Zoledronic acid has not been studied in patients with severe renal impairment and is not recommended in this setting. The update panel suggests that bone-modifying treatment continue for up to 2 years. Less frequent dosing has been evaluated and should be considered in patients with responsive or stable disease. Continuous use is at the discretion of the treating physician and the risk of ongoing skeletal morbidity. Retreatment should be initiated at the time of disease relapse. The update panel discusses measures regarding osteonecrosis of the jaw. Additional information is available at www.asco.org/hematologic-malignancies-guidelines and www.asco.org/guidelineswiki .
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Catalano, John, Belch, Andrew , Cavo, Michèle , Pinto, Antonello, Banos, Anne , Tiab, Mourad, Delforge, Michel , Cavenagh, Jamie, Lee, Je‐Jung , Chen, Christine , Oriol, Albert , Rubia, Javier de la , White, Darrell , Binder, Daniel, Moreau, Philippe , Perrot, Aurore , Arnulf, Bertrand , Qiu, Lugui , Roussel, Murielle , Boyle, Eileen M. , Manier, Salomon , Mohty, Mohamad , Avet‐Loiseau, Hervé , Leleu, Xavier , Ervin‐Haynes, Annette, Chen, Guang , Houck, Vanessa, Benboubker, Lotfi , Hulin, Cyrille , Pinto, Antonio , Moreau, Philippe , Perrot, Aurore , Boyle, Eileen M , Facon, Thierry T.F. , Dimopoulos, Meletios Α. , Dispenzieri, Angela , Pinto, Antonello, Weisel, Katja C , Ludwig, Heinz , Bahlis, Nizar Jacques , Geraldes, Catarina , Lu, Jin Ping , Anderson, Kenneth C. , Attal, Michel , Qiu, Lugui , Roussel, Murielle , Pinto, Antonio , Oriol, Albert , Mohty, Mohamad

Mayo Clinic

Blood | November 17, 2017 | Volume: 131 | Issue: 3 | Pages: 301-310

10.1182/blood-2017-07-795047 | PMID 29150421 Get It

Key Points Rd continuous significantly extended OS compared with MPT and resulted in comparable OS to that with Rd18 in patients with multiple myeloma. Patients achieving complete or very good partial response with Rd benefited greatly from continuous vs fixed treatment in terms of PFS.
Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes
Mahar, Alyson , Compton, Carolyn C. , Halabi, Susan , Hess, Kenneth R. , Weiser, Martin R. , Groome, Patti A. , Mahar, Alyson L , Compton, Carolyn, Halabi, Susan

Mayo Clinic

Journal of Surgical Oncology | August 2, 2017 | Volume: 116 | Issue: 8 | Pages: 969-982

10.1002/jso.24774 | PMID 28767139 Get It

Integrating diverse types of prognostic information into accurate, individualized estimates of outcome in colorectal cancer is challenging. Significant heterogeneity in colorectal cancer prognostication tool quality exists. Methodology is incompletely or inadequately reported. Evaluations of the internal or external validity of the prognostic model are rarely performed. Prognostication tools are important devices for patient management, but tool reliability is compromised by poor quality. Guidance for future development of prognostication tools in colorectal cancer is needed.
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
Auclair, Daniel , Kelloff, Gary J. , Sigman, Caroline C. , Avet‐Loiseau, Hervé , Farrell, Ann T. , Gormley, Nicole , Kumar, Shaji , Munshi, Nikhil C. , Cavo, Michèle , Davies, Faith E. , Bacco, Alessandra Di , Dickey, Jennifer S., Gutman, Steven, Higley, Howard R., Hussein, Mohamad A., Jessup, J. Milburn , Little, Richard F. , Loberg, Robert D., Lohr, Jens G. , Mukundan, Lata , Omel, James, Pugh, Trevor J. , Reaman, Gregory H. , Robbins, Michael , Sasser, A. Kate, Valente, Nancy, Zamagni, Elena , Anderson, Kenneth C. , Landgren, Ola , Kirsch, Ilan R. , Pugh, Trevor J , Davies, Faith E , Gormley, Nicole , Zamagni, Elena

Mayo Clinic

Clinical Cancer Research | April 20, 2017 | Volume: 23 | Issue: 15 | Pages: 3980-3993

10.1158/1078-0432.ccr-16-2895 | PMID 28428191 Get It

Abstract Treatment of myeloma has benefited from the introduction of more effective and better tolerated agents, improvements in supportive care, better understanding of disease biology, revision of diagnostic criteria, and new sensitive and specific tools for disease prognostication and management. Assessment of minimal residual disease (MRD) in response to therapy is one of these tools, as longer progression-free survival (PFS) is seen consistently among patients who have achieved MRD negativity. Current therapies lead to unprecedented frequency and depth of response, and next-generation flow and sequencing methods to measure MRD in bone marrow are in use and being developed with sensitivities in the range of 10−5 to 10−6 cells. These technologies may be combined with functional imaging to detect MRD outside of bone marrow. Moreover, immune profiling methods are being developed to better understand the immune environment in myeloma and response to immunomodulatory agents while methods for molecular profiling of myeloma cells and circulating DNA in blood are also emerging. With the continued development and standardization of these methodologies, MRD has high potential for use in gaining new drug approvals in myeloma. The FDA has outlined two pathways by which MRD could be qualified as a surrogate endpoint for clinical studies directed at obtaining accelerated approval for new myeloma drugs. Most importantly, better understanding of MRD should also contribute to better treatment monitoring. Potentially, MRD status could be used as a prognostic factor for making treatment decisions and for informing timing of therapeutic interventions. Clin Cancer Res; 23(15); 3980–93. ©2017 AACR.